Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S1-S4 , March 2004

Bimatoprost: Establishing its role in glaucoma management

  • L.Jay Katz, MD, FACS

      Affiliations

    • Corresponding Author InformationReprint address: L. Jay Katz, MD, Wills Eye Hospital, 900 Walnut Street, Philadelphia, PA 19107-5599.

References 

  1. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–440
  2. Asrani S, Zeimer R, Wilensky J, et al.  Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142
  3. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487–497
  4. DuBiner H, Cooke D, Dirks M, et al.  Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(Suppl 4):S353–S360
  5. FDA. Table 1. FY 2000 Priority NDA and BLA Submissions Approved in FY 00, Office of Planning. FDA. Available at: www.fda.gov/oc/pdufa/report2001/appendixb.html
  6. Gandolfi S, Simmons ST, Sturm R, et al.  Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110–121
  7. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95–104
  8. Heijl A, Leske MC, Bengtsson B, et al.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279
  9. Higginbotham EJ, Schuman JS, Goldberg I, et al.  One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293
  10. Juzych MS, Zimmerman TJ. Beta-blockers. In:  Zimmerman TJ editors. Textbook of Ocular Pharmacology, Chapter 23. Philadelphia: Lippincott-Raven; 1997;
  11. Kass MA, Heuer DK, Higginbotham EJ, et al.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713 discussion 829–30
  12. Lichter PR, Musch DC, Gillespie BW, et al.  Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–1953
  13. Netland PA, Landry T, Sullivan EK, et al.  Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472–484
  14. Noecker RS, Dirks MS, Choplin NT, et al.  A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63
  15. Packer M, Brandt JD. Ophthalmology's botanical heritage. Surv Ophthalmol. 1992;36:357–365
  16. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703
  17. Preferred Practice Pattern: Primary Open-Angle Glaucoma. American Academy of Ophthalmology; 2000;
  18. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S361–S368

PII: S0039-6257(03)00188-7

doi: 10.1016/j.survophthal.2003.12.013

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S1-S4 , March 2004

Article Tools